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Abstract
Cervical cancer remains one of the greatest killers of women worldwide. It is difficult to foresee a
dramatic increase in cure rate even with the most optimal combination of cytotoxic drugs, surgery,
and radiation; therefore, testing of molecular targeted therapies against this malignancy is highly
desirable. A number of epigenetic alterations occur during all stages of cervical carcinogenesis in
both human papillomavirus and host cellular genomes, which include global DNA hypomethylation,
hypermetylation of key tumor suppressor genes, and histone modifications. The reversible nature
of epigenetic changes constitutes a target for transcriptional therapies, namely DNA methylation
and histone deacetylase inhibitors. To date, studies in patients with cervical cancer have
demonstrated the feasibility of reactivating the expression of hypermethylated and silenced tumor
suppressor genes as well as the hyperacetylating and inhibitory effect upon histone deacetylase
activity in tumor tissues after treatment with demethylating and histone deacetylase inhibitors. In
addition, detection of epigenetic changes in cytological smears, serum DNA, and peripheral blood
are of potential interest for development of novel biomolecular markers for early detection,
prediction of response, and prognosis.
Overview of cervical cancer
Epidemiology and treatment
Cervical cancer remains one of the greatest killers of
women worldwide. According to Globocan 2000, it is esti-
mated that in 2000 the numbers of patients diagnosed
with and those who died from this disease were 470,606
and 233,372, respectively [1]. It is remarkable that these
rates occur despite the fact that cervical cancer is a model
for early detection due to its long and relatively well-
known natural history, which offers an excellent opportu-
nity for its detection before lesions become invasive [2].
Cervical cancer is currently staged clinically according the
International Federation of Gynecology and Obststrics
(FIGO) guidelines. In terms of treatment, invasive disease
can be divided into three main groups: 1) early stage
going from microinvasive disease IA1, IA2 to macroscopic
disease confined to cervix and measuring <4 cm, IB1; 2)
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locally advanced FIGO stages IB2-IVA, and 3) IVB and
recurrent disease [3].
Treatment of early stages
The recommended treatment for IA1 patients is either a
local procedure such as conization or total hysterectomy
depending on the patient's desire to remain fertile,
whereas for IA2 patients the recommended procedure is a
radical one including pelvic lymphadenectomy. On aver-
age, 8% of cases shows positive pelvic lymph nodes. As
many women at this disease stage deserve to preserve fer-
tility, radical trachelectomy is becoming an option for
these patients. The same can apply for IB1 patients. In
early cases that are surgically treated, the presence in the
surgical specimen of a combination of intermediate-risk
factors (vascular and lymphatic permeation, tumor size
>2 cm, and deep cervical stroma invasion) or high-risk
factors (positive pelvic lymph nodes, parametrial infiltra-
tion, and positive surgical margins) dictates use of adju-
vant radiation or chemoradiation respectively. As a group,
the prognosis of early-stage cases is fairly good with 5-year
survival exceeding 90% [4,5]
Treatment of locally advanced stages
Results of treatment for these patients are far from opti-
mal. In this regard, treatment of locally advanced cervical
cancer has experienced no major changes for nearly 80
years during which exclusive radiation was considered the
standard of care; thus, 5-year survival for stages IB2, IIB,
IIIB, and IVA are 72.2, 63.7, 41.7, and 16.4%, respectively,
according the 1998 Annual Report on the Results of Treat-
ment in Gynaecological Cancer [6]. The lengthy perma-
nence of this unimodal treatment was due, on the one
hand, to the classical concept that cervical cancer is a dis-
ease that progresses in an orderly fashion (local, then
regional, and at the very last, systemic); therefore, it could
be effectively treated with a local modality such as radia-
tion instead of a systemic modality such as chemotherapy.
On the other hand, the role of surgery for locally advanced
cases failed to treat the disease successfully by radical sur-
gical procedures [7]. Over the last 20 years, however, an
increasingly number of trials that incorporate either
chemotherapy and/or surgery with radiation (neoadju-
vant chemotherapy followed by radiation, neoadjuvant
chemotherapy followed by surgery plus minus adjuvant
radiation, and concurrent chemoradiation) have been
performed in an attempt to improve treatment results.
Radiation concomitant with cisplatin-based chemother-
apy is considered the current standard of treatment. This
combined modality produces an absolute increase in 5-
year survival of 12% as compared with radiation alone.
On the other hand, neoadjuvant chemotherapy when fol-
lowed by surgery – but not when followed by radiation –
yields a 15% increase in absolute 5-year survival. These
data emerged from three meta-analyses of the literature
based on individual patient analysis [8,9].
Treatment of IVB and recurrent disease
Patients with cervical cancer may present at diagnosis with
distant metastases (stage IVB) or have, after primary treat-
ment, pelvic recurrence, distant metastases, or a combina-
tion of both. Recurrence rates vary from up to 20% to 70%
in early stages and locally advanced disease, respectively
[10,11] and the majority of recurrences occur within 2
years of diagnosis. At this stage, cervical cancer is even
more difficult to treat because this clinical situation is the
result of a more malignant phenotype resulting from
accumulation of genetic defects during tumor progression
and previous therapies; thus, the tumor at this stage is
commonly resistant to chemotherapy. Moreover, these
patients frequently have a poor performance status that
limits use of agressive chemotherapy and the majority of
patients die as a result of uncontrolled disease. In this set-
ting, the few patients who recur after initial surgical treat-
ment can be salvaged with concurrent chemoradiation if
the disease is local or locoregional [12]. Those who receive
primary radiation or chemoradiation and have pelvic dis-
ease can be offered an ultraradical procedure such as pel-
vic exenteration; nonetheless, this procedure is currently
limited to patients with small and central tumors that in
these situations, pelvic exenteration may offer 5-year sur-
vival for up to 50% of patients [13]. Although some efforts
have been devoted to extending the exenterative proce-
dures to patients with higher disease burdens by use of
intraoperative radiation [14], laterally extended pelvic
exenteration [15], or pre-exenterative chemotherapy [16]
none of these options are widely used. Unfortunately,
patients with IVB and those with distant metastases – with
or without pelvic relapse – have no option other than sys-
temic chemotherapy that in this setting has limited value;
cisplatin is the most active single agent [17] and more
recently in combination with topotecan has shown a
modest increase in time to progression and median sur-
vival as compared with single agent cisplatin. In any case,
median survival remains between 6 and 12 months [18].
Molecular pathogenesis of cervical cancer
Human papillomavirus
Current experimental and epidemiologic information
undoubtedly points to the human papillomavirus (HPV)
as the primary causal agent in development of cervical car-
cinoma. Therefore, the study of its carcinogenic role con-
tinues to represent the mainstream research on the
molecular biology of cervical cancer, with the idea that
prophylactic and therapeutic applications of knowledge
from this field could benefit millions of women afflicted,
or at risk to be afflicted, with HPV-induced cervical cancer.Molecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
Page 3 of 24
(page number not for citation purposes)
HPV classification is predicted on DNA sequence homol-
ogy. At least 200 types have been identified and these have
been classified into 16 groups [19]. Genital HPVs are clas-
sified according to their potential to induce malignant
transformation as follows: high-risk types (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82); probable
high-risk types (26, 53, and 66), and low-risk types (6, 11,
40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108) [20].
Among high-risk strains, HPV 16 and 18 are those most
closely associated with cervical carcinoma and are found
in >50% and 20% of squamous cell carcinomas, respec-
tively [21].
A large body of knowledge supports the view that high-
risk HPV types (HR-HPV) have the ability to transform
cells into a malignant phenotype. Nevertheless, only a
minority of cervical lesions infected with HR-HPV inevita-
bly progress to cervical carcinoma, as indicated by fre-
quent spontaneous clearance of HPV infection and the
long delay between onset of persistent infection and
emergence of the malignancy. For that reason, studies
have been focused on analyzing the participation of pos-
sible viral and cellular factors governing HPV-induced
malignancy.
HPV structure
Human papillomaviruses (HPV) belong to the Papova-
viridae family. They consist of a 72-capsomere capside
containing the viral genome. Capsomers are composed of
two structural proteins: the 57 kD late protein L1, which
accounts for 80% of the viral particle, and the 43–53 kD
minor capside protein L2. The HPV genome consists of
eight kilobasepairs (Kbp) and is a double-stranded DNA
molecule. Arrangement of the 8–10 open reading frames
(ORFs) within the genome is similar in all papillomavirus
types, and partly overlapping ORFs are arranged on a sole
DNA strand. The genome can be divided into three
regions: the long control region (LCR) without coding
potential; the region of early proteins (E1–E8), and the
region of late proteins (L1 and L2) [22].
Early gene products
E1 and E2 encode proteins that are vital for extrachromo-
somal DNA replication and completion of the viral life
cycle [23]. A hallmark of HPV-associated cervical carci-
noma is loss of the expression of viral E2 protein [24]. A
fusion product consisting of the small E8 ORF with part of
the E2 protein has been described. This fusion protein is
able to repress viral DNA replication as well as transcrip-
tion, and is therefore believed to play a major role in the
maintenance of viral latency observed in the basal cells of
infected epithelium [25,26]. The E4 protein is expressed
in the later stages of infection when complete virions are
being assembled, and is not known to have transforming
properties; however, it is considered to play an important
role in the maturation and replication of the virus [27].
The E5 in open reading frame is often deleted in cervical
carcinoma cells, indicating that it might not be essential in
maintaining the malignant transformation of the host
cell. Nevertheless, it has been reported that E5 protein
possesses a weak transforming activity [28].
E6 and E7 proteins
E6 and E7 are the most important oncogenic proteins.
Transcription of E6 and E7 genes has been observed to
occur always in cervical carcinomas, being the first indica-
tion of a main role of these viral genes in HPV-associated
tumorigenesis. The immortalization and transforming
potential of E6 and E7 proteins have been demonstrated
in tissue culture and in experimental animal models [29].
From the studies of E6-p53 and E7-pRb models, numer-
ous actions have been identified of viral gene products on
cellular proteins. Therefore, several findings hint at possi-
ble ways by which HPV-infected cells may escape controls
governing cell growth and proliferation.
The E6 protein of high-risk HPV anogenital types shows
weak oncogenic potential in the majority of established
cell lines, and cooperation with E7 protein is required for
full transforming capacity. Discovery of the inactivation of
the tumor suppressor genes p53 and pRB by E6 and E7
oncoproteins provided a basic explanation of how high-
risk HPV types induce their oncogenic effects on cervical
cells [30]. E6 has many interactions with cellular proteins;
nevertheless, its key action is inhibition of the function of
tumor suppressor protein p53 by enhancing its degrada-
tion through the ubiquitin pathway [31,32]. To inhibit
p53 function, E6 requires a cellular protein called E6-asso-
ciated protein (E6AP). In non-infected cells, ubiquitin-
mediated degradation of p53 is triggered by the mdm-2
protein, while in HR HPV-infected cells the E6-E6AP com-
plex replaces mdm-2 in control of cellular p53 levels. This
shift shortens the p53 half-life and reduces its levels in cer-
vical carcinoma cells to less than one half of the level
found in normal ephithelial cells [33]. It is known that
increase in p53 levels plays a critical role in the induction
of genes that results in cell cycle arrest [34], allowing
repair of damaged DNA or activation of apoptotic path-
ways [35]. Therefore, cells expressing E6 maintain low lev-
els of functional p53, altering normal response to DNA
damage and favoring accumulation of genomic muta-
tions. Binding of the E7 oncoprotein on pRB provides a
complementary function. Binding releases transcription
factor E2F that activates expression of genes that stimulate
DNA synthesis in the cell. If earlier E6 action had freed the
same cell from p53 control, that cell survives into the S
phase with damaged DNA and, through E7 action, is able
to replicate the HPV DNA [36]. Oncogenic properties of
E6 and E7, as well as their effects on p53 and pRB, have
provided the general basis for further investigations of theMolecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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role of HPV in carcinogenesis in the HPV-infected cervix.
Research in the action of the two oncoproteins have
shown how they subvert key cell cycle and regulatory
processes such as cyclins, cyclin-dependant kinases
(CDKs), and cyclin-dependant kinase inhibitors (CDIs),
among other interactions, to transform and immortalize
the host cell [37].
DNA integration
HVP DNA is usually extrachromosomal or episomal in
benign cervical precursor lesions. Cancer tissues may con-
tain both episomal and integrated HPV DNAs at the same
time, although integration appears to occur more fre-
quently in HPV 18- than in HPV 16-associated cervical
cancer [28]. During HPV DNA integration, the viral
genome usually breaks in the E1/E2 region. The break
generally leads to loss of the E1 and E2 regions. Loss of E2
results in uncontrolled and increased expression of E6 and
E7 oncogenic proteins. Increased expression of E6 and E7,
meanwhile, has been observed to lead to malignant trans-
formation of host cells and to tumor formation [38]. HPV
viral integration into host genome DNA is associated with
progression from polyclonal to monoclonal status in cer-
vical intraepithelial neoplasia (CIN), and these events
play a fundamental role in the progression from low- to
high-grade cervical neoplasia [39].
Epigenetics
Epigenetics can be defined as the study of genoma func-
tion that is contained outside of DNA itself and by means
of which stable alterations in gene expression are set. Epi-
genetics is a well-established phenomenon that plays a
major role in a diversity of biological processes such as
embryonic development, cancer biology, and immune
system response, among many others. The two most
widely studied epigenetic changes are DNA methylation
and histone acetylation; however, the picture is much
more complicated than this, with new players coming
onto the scene such as the RNA interference phenome-
non, which has proven to be implicated in transcriptional
silencing through small duplex RNA molecules that
recruit silencing complexes to the chromatin [40,41,22].
DNA methylation
DNA methylation is a covalent chemical modification
that occurs at the cytosine ring, resulting in the addition
of a methyl (CH3) group at the carbon 5 position. Accord-
ing to the fact that DNA is made up of four bases and that
therefore 16 possible dinucleotide combinations can
occur, the CpG dinucleotide should have a frequency of
6%. However, the actual presence is only 5–10% of its
predicted frequency. The human genome is not methyl-
ated uniformly and contains regions of unmethylated seg-
ments interspersed with methylated region. In contrast to
the remainder of the genome, smaller regions of DNA,
called CpG islands – and ranging from 0.5–5 kb and
occurring on average every 100 kb – have distinctive prop-
erties. These regions are unmethylated, GC-rich (60–
70%), have a ratio of CpG to GpC of at least 0.6, and thus
do show no suppression of dinucleotide CpG frequency.
Approximately one half of all genes in humans have CpG
islands, and these are present in both housekeeping genes
and genes with tissue-specific patterns of expression [43-
46]. At least three functional DNA methyltransferases
(DNMTs) have been identified; the most abundant is
DNMT1, which preferentially methylates hemi-methyl-
ated DNA. DNTM1 localizes to replication foci and is
responsible for maintaining proper methylation levels
during replication and possibly DNA repair [47,48].
Other known functional methyltransferases are DNMT3a
and DNMT3b, which are responsible for de novo methyl-
ation during embryogenesis [49]. DNMT3a and DNMT3b
have equal preferences for hemi-methylated and non-
methylated DNA, and thus have been classified as de novo
methyltransferases[50]. In addition to DNMTs, the
machinery of methylation includes demethylases, methyl-
ation centers triggering DNA methylation, and methyla-
tion protection centers [51]. The effect of DNA
methylation on gene transcription can only be seen in the
context of chromatin remodeling players. DNA methyla-
tion can directly interfere with transcriptional factor bind-
ing and thus inhibit replication [52], in addition to the
ability of DNA methyltransferases DNMT1, DNMT3a, and
DNMT3b to repress transcription in a methylation-inde-
pendent manner [53]. Methyl-CpG binding proteins,
which can recognize methylated DNA, have been shown
to associate with large protein complexes containing
HDACs and chromatin-remodelling activities, and it has
also been suggested that DNA methylation could produce
gene silencing by methyl binding domain proteins that
recruit histone methyltransferases, which methylate lysine
9 in histone H3 and subsequently repress gene transcrip-
tion [54]; as a result, histones are deacetylated and gene
transcription is most often repressed.
Histones and post-translational modifications
How double-strand DNA is packaged into the dynamic
structure of chromatin is crucial for the process of tran-
scriptional control by regulating transcription factor
accessibility to DNA regulatory sequences. Chromatin is
constituted of nucleosomes, which are comprised of 146
base pairs of DNA wrapped around a core of two copies
each of H2A, H2B, H3, and H4 histone proteins. These
proteins suffer post-translational modifications that play
a prominent role in gene expression regulation and signal
transduction pathways such as methylation, acetylation,
ubiquitination, phosphorylation, and sumoylation,
which determine chromatin architecture and ultimately
gene transcription [57].Molecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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The most widely studied modification is acetylation.
Addition of charge-neutralizing acetyl groups to lysine res-
idues on histones disrupts interactions with DNA, result-
ing in chromatin decompactation, greater access of DNA
to transcription factors, and the presence of a transcrip-
tionally active genomic locus. This post-translational
modification depends on the net local balance between
activities of histone acetyltransferase (HAT) and histone
deacetylase (HDAC). In general, increased levels of his-
tone acetylation (hyperacetylation) are found in more
decondensed euchromatin, whereas decreased levels of
acetylation (hypoacetylation) are characteristic of more
condensed heterochromatin [58]. However, this mechan-
ical model is an oversimplification of how gene transcrip-
tion is regulated as additional histone modifications
influence transcription [59].
Histone methylation can occur on lysine and arginine res-
idues, giving the cell another layer of regulatory options,
for example, lysine 9 in histone H3. It is currently known
that histone arginine methylation is more dynamic, corre-
lating well with gene activation and its loss from target
arginines in H3 and H4 with gene inactivation. In con-
trast, lysine methylation appears to be a more stable mark.
In this sense, methylation of lysine 4 in histone H3 corre-
lates with gene activation, whereas methylation of lysines
9 and 27 in histone H3 correlates with repression [61-63].
Phosphorylation is another important and long-appreci-
ated histone modification often associated with chromo-
some/chromatin condensation that includes mitosis,
meiosis, apoptosis, and DNA damage, events regulated by
different histone kinases (for example, members of the
Aurora/AIK family [64-66]. Along with this post-transla-
tional modification of histone proteins, sequence-specific
DNA binding by transcription factors and other protein
remodeling factors determine a histone code for gene-spe-
cific transcriptional control that may dictate which modi-
fication or specific combinations of histone modifications
can affect distinct downstream events by altering chroma-
tin structure and/or generating a binding platform for pro-
tein effectors that can specifically recognize the
modification and initiate gene transcription or repression
[67].
Epigenetic alterations in cancer
Because of the close interplay between DNA methylation
and histone modifications, it is expected that both mech-
anisms are operating in disease processes such as cancer;
nonetheless, for the majority of tumor types the epige-
netic defects could be just one of the many molecular cell
alterations that lead to the malignant phenotype.
DNA methylation and cancer
Abnormalities in DNA methylation have long been asso-
ciated with cancer. Both hypo- and hypermethylation play
a prominent role in carcinogenesis, and their contribution
shows scarcely defined boundaries. It has long been
known that in cancer cells both alterations coexist: malig-
nant tumors show global hypomethylation and regional
hypermethylation. Whether one must precede the other
or whether both should start at the same time remains to
be elucidated. In terms of carcinogenesis, the first observa-
tions in fact were done on hypomethylation [69]; later,
the discovery of regional hypermethylation as a means to
silence the tumor suppressor genes expression gained the
most attention [70].
Hypermethylation and gene silencing
Observations that tumor suppressor genes can be inacti-
vated not only through structural changes (mutation,
deletion) but also by lack of expression due to promoter
hypermethylation positioned tumor suppressor gene epi-
genetic silencing as a well-established oncogenic process
[71]. The first suppressor gene known to be hypermethyl-
ated and silenced was RB [72], which was followed by
multiple publications describing similar findings for a
variety of tumor suppressor genes, among them p16,
MLH1, VHL, and E-cadherin [73].
Whether gene promoter hypermetylation is the cause or
consequence for the tumor suppressor gene silencing is
still a matter of controversy; nevertheless, these views are
not mutually exclusive. That DNA methylation is causal
has been shown by the ability of diverse pharmacologic
compounds and molecular techniques to reactivate gene
expression upon inhibition of DNA methylation in cancer
cells [74].
On the other hand, other findings suggest that hyper-
methylation-induced gene silencing could be secondary
to changes that determine gene expression, such as chro-
matin modification, so that methylation helps to main-
tain the silenced status of the gene. Strong support for the
second view came from experiments showing that meth-
ylation of histone H3 lysine 9 – that is, chromatin modi-
fication – occurred, along with re-silencing of p16  in
absence of DNA methylation in cells in which p16 had
previously been activated by knocked out of DNA methyl-
transferase [75] and by data demonstrating p16 silencing
in mammary epithelial cells that had escaped senescense
and had demethylated the promoter [76].
Hypomethylation and gene activation
It is known that tumor cells have global DNA hypometh-
ylation that can be as high as 60% less than their normal
counterparts [77]. This hypomethylation occurs mainly in
the body of genes (coding regions and introns), as well as
in pericentromeric regions of chromosomes rich in repet-
itive DNA sequences [79]. Interestingly, hypomethylation
is progressive from premalignant conditions to fullyMolecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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developed malignancies [80]. The main mechanisms put
forward in attempting to explain cancer causation by
hypomethylation include chromosome instability and
reactivation of transposable elements and/or inappropri-
ate gene activation [81]
There are two pieces of convincing evidence linking
hypomethylation with chromosomal instability. The con-
genital disorder ICFs syndrome (immunodeficiency,
chromosomal instability, and facial anomalies) caused by
mutations at DNMT3b demonstrates loss of methylation
in classical satellite DNA and mitogen-inducible forma-
tion of bizarre multiradial chromosomes that contain
arms from chromosomes 1 and 16 [82]. This disorder,
however, is not associated with cancer, but common
somatic tumors such as breast, ovarian, and other epithe-
lial tumors commonly have unbalanced chromosomal
translocations with breakpoints in the pericentromeric
DNA of chromosomes 1 and 16 [83]. In mouse models
with an inactivated allele of NF1 and p53 genes, introduc-
tion of a hypomorphic DNMT1 allele caused a 2.2-fold
increase in LOH frequency [84].
Finally, some reports have stressed the fact that many CpG
islands are normally methylated in somatic tissues [85],
and that demethylation could lead to activation of nearby
genes such as HRAS. Indeed, experimental demonstration
exists that hypomethylation leads to activation of genes
important for cancer development, including promoter
CpG demethylation and overexpression of 14-3-3sigma,
maspin, heparanase, and S100A4  in several tumor types
[86-88]. The question here is whether over-expression was
indeed caused by hypomethylation or whether promoters
are hypomethylated secondary to its high transcriptional
activity. There are data showing that the sole hypomethyl-
ation as achieved by pharmacologic means is not suffi-
cient to activate gene expression. In this context, some
genes are not permisive for expression; this means that
despite the fact that methylation is relieved the necessary
ancillary factors to activate transcription are not present.
Others are permissive and therefore reactivated by
demetylation, whereas for others hypomethylation does
not affect their levels of expression but can be over-
expressed due to activation of signalling pathways known
to activate them [89].
Chromatin and cancer
All classical genetic alterations – for instance, mutations
in oncogenes or tumor suppressor genes of malignant
cells – eventually affect gene transcription (mutant Ras,
HER2 amplifications), or are transcription factors in
themselves (c-myc, p53). It is therefore not surprising that
the machinery of transcription control could be directly
involved in the carcinogenesis process. Although the com-
plex nature of the regulation of transcription is clear, cer-
tainly a disruption in the balance of activities of enzymes
in charge of maintaining histone acetylation status is
expected to occur in cancer. Among histone acetylases, the
coding genes of p300/CBP have been found altered in
some neoplasms. Mutations have been observed in epi-
thelial tumors such as lung, esophageal, ovarian, and gas-
tric tumors [90-93]. Chromosomal translocations
involving CBP or p300 that in turn disrupt transcription
by its fusion with partern genes are well-described molec-
ular defects leading to hematologic malignancies such as
some forms of acute myeloid leukemias [94,95]. Histone
deacetylase activity leading to aberrantly repressed tran-
scription was one of the first described leukemogenesis
events. In acute promyelocytic leukemia, PML-RARα
translocation generates a fusion gene product that
represses transcription by associating with a co-repressor
complex that contains HDAC activity [96]. Similar mech-
Table 1: Main epigenetic alterations in cervical cancer
Alteration Meaning
HPV-related
Methylation of HPV-E2 binding sites De-repression of E6 and E7 HPV oncoproeteins?
Methyation at HPV-E6 and E7 LCR Cause or consequence of E6/E7 over-expression?
E6 and/or E7 interaction with DNMTs? Silencing of cellular tumor suppressor genes?
Interaction between E7 with HDACs Aid for cell transformation
Interaction between E6 with HATs Aid for cell transformation
Host cell-related
Regional DNA hypermethylation Silencing of tumor suppressor genes
Global DNA hypomethylation Genomic instability?, oncogen over-expression?
Abnormal pattern of chromatin Unknown
Loss of imprinting at H19/IGF2 loci Tumor progression?
H3 hyper-phosphorylation & acetylation Associated with carcinogenesis ProgressionMolecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
Page 7 of 24
(page number not for citation purposes)
anisms account for other types of leukemia and lympho-
mas such as AML1-ETO and LAZ3/BCL6, respectively
[97,98].
Despite the fact that participation of DNA methylation
and chromatin in the carcinogenic process is unquestion-
able, it must be borne in mind that the split of epigenetics
and genetics as separate types of defects in cancer is very
artificial. In fact, according to the definition of epigenetics
as genetic information not contained in the DNA
sequence itself, current evidence demonstrates that pri-
mary genetic defects (mutations in genes with no known
primarily methylating or chromatin-modifying activity
such as growth factor receptors, adhesion molecules, etc,,
or mutations in genes that in themselves affect DNA
methylation or chromatin such as DNMTs or HAT/
HDAC) are those leading to altered DNA methylation and
chromatin changes. Demonstration that exogenous or
endogenous carcinogens without causing primarily gene
mutations lead to epigenetic abnormalities should prove
that epigenetics is by itself one of the carcinogenic steps.
Epigenetic alterations in cervical cancer
Because infection with high-risk types of human papillo-
mavirus is needed for cervical cancer development, it is
important to consider the epigenetic changes occurring in
the viral genome that can influence the virus-driven carci-
nogenic process as well as epigenetic changes in the host
genome. Table 1 summarizes epigenetic alterations found
in cervical cancer.
HPV and methylation
The realization that viral infections, by insertion of viral
genes into host genomes, can trigger host defense mecha-
nisms such methylation machinery activation has aroused
interest in the study of epigenetic events occurring in both
virus and host genomes [99]. Human genomes harbor
DNA sequences resembling retroviral long terminal
repeats and the transposable elements, and indeed there
are indications that under some situations inappropiate
"activation" of these normally silenced sequences could
play a role in the carcinogenic process [100]. In addition,
it is also established that some viruses can find ways to
adapt different tactics to regulate expression of their genes
through modulation of DNA methylation; thus, a virus
may silence activation of its genes in a manner that favors
establishment of persistent infection and evades the host
immune defense [101]. In addition to this, viral oncopro-
teins can possess the ability to modulate directly or indi-
rectly the methylation machinery in order to silence
cellular genes that could interfere with its tumor promot-
ing actions. A very illustrative example of this is how the
Epstein-Barr virus oncogene product, latent membrane
protein 1, induces downregulation of E-cadherin gene
expression via activation of DNA methyltransferases
[102].
The role of HPV genome DNA hypermetylation has of late
been the subject of study. One of the first indications of
the importance of DNA methylation and viral gene
expression came from studies of cell transfection with
HPV-16 in-vitro methylated genomes, demonstrating that
under these circumstances DNA is transcriptionally
repressed [103]. In SiHa and CasKy cell lines that harbor
HPV-16 and have a couple of and multiple viral genome
copies, respectively, a conserved profile of CpG hyper and
hypomethylation was found by using scanning with the
restriction enzyme McfBC. Hypermethylation was found
in genomic segments overlying late genes, while the long
control region and the E6 and E7 oncogenes were
unmethylated in SiHa cells. Interestingly, evaluation of
smears of normal, precursor, and invasive lesion smears
of 81 patients showed that as lesion severity increases,
there is progressive hypomethylation on these LCR and E6
gene regions; thus, hypermethylation was found in 52%
of smears from asymptomatic women, in 21.7% of prein-
vasive lesions, and only in 6.1% of invasive-case smears.
These findings lead the authors to postulate that neoplas-
tic transformation can be suppressed by gene hypermeth-
ylation, whereas hypometylation accompanies or causes
cancer progression [104]. These findings however, were
not totally coincident in another study that studied L1 and
LCR regions by bisulfite modification in 115 clinical sam-
ples. First, high heterogeneity on methylation status was
noted among patients and even in different samples of the
same patient. As expected, methylation frequency was ca.
30% in the L1 region and lower in other positions, partic-
ularly at a CpG site located in the linker between two
nucleosomes positioned over HPV-16 enhancer and pro-
moter. However, methylation at most sites was consist-
ently higher in carcinomas as compared with dysplasia,
possibly related to the tandem repetition and chromo-
somal integration that occurs in invasive lesions [105]. In
another study performed in two HPV-18 cervical cancer
cell lines, HeLa and C4-1, and clinical samples, there was
also clonal heterogeneity in the methylation status of the
different regions analyzed. When it came to clinical sam-
ple analysis, there was complete or partial HPV-enhancer
methylation in three of six tumors and complete demeth-
ylation in eight smears from asymptomatic patients. Like-
wise, promoter methylation was found in three of six
cancers and in four of six smears [106]. The latter two
studies suggest that methylation status of viral oncogenes
in lesions perhaps is perhaps solely the result of their tran-
scriptional activity level and not a causal event for neo-
plastic progression.
Further data on the influence of DNA methylation in the
HPV life cycle comes from another study that focused onMolecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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methylation of E2, the early gene that contributes to mul-
tiple biological processes including viral transcription and
viral DNA replication. It has been shown that the capacity
of E2 protein to bind E2BS in vitro is inhibited by methyl-
ation of these cytosines [107]. Kim et al. performed a
methylation analysis by bisulfite modification of E2 bind-
ing site within LCR in DNA isolated from an immortal-
ized epithelial cell line isolated from an HPV 16-infected
patient and demonstrated that this region is selectively
hypomethylated in the highly differentiated cell popula-
tions, whereas poorly differentiated basal-like cells were
heavily methylated particularly in E2 binding sites. These
observations may indicate that the methylation state of
the viral genome, and particular that of E2BSs, may vary
during the viral life cycle, providing a novel means for
modulating E2 function as infection progresses [108]. It
will be of major interest to analyze human papillomavirus
oncogene expression in cervical tumors before and after
treatment of patients with DNA methylation inhibitors.
Hypermethylated genes in cervical cancer
There are numerous reports demonstrating that tumor
suppressor genes belonging to nearly every cancer path-
way or function category have silenced or diminished
their expression due to abnormal promoter hypermethyl-
ation in cervical carcinoma (Table 2).
Apoptosis-related genes
It is now established that failure of cells to undergo apop-
tosis is crucial for cancer development and progression,
but most importantly this phenomenon participates in
intrinsic or acquired resistance of cancer cells to chemo-
therapy and radiation. Identification of points in the
apoptotic pathway at which dysregulation occurs would
potentially open up new therapeutic opportunities in sit-
uations where conventional cancer treatments fail. One of
the first indications of the role of methylation for inacti-
vation of key apoptotic genes came from the study show-
ing that Apaf-1 was silenced in melanoma instead of
being lost or mutated [109].
Studies analyzing apoptosis-related genes that can be
inactivated by methylation in cervical cancer are limited.
One study has shown that decoy receptors DcR1 and
DcR2 can be the target for abnormal methylation that
leads to their silencing [110]. These molecules are mem-
bers of the tumor necrosis factor receptor superfamily,
which includes TNFR1, Fas, and the decoy receptors for
TRAIL. Upon engagement by their respective ligands,
TNFR1 and FAS recruit adaptor molecules and activate a
cascade of caspases. Death-inducing decoy receptors DR4
and  DR5  and  DcR1  and  DcR2  are structurally related;
nonetheless,  DcR1  completely lacks the intra-cellular
death domain and DcR2 contains a truncated, nonfunc-
tional death domain and appears unable to induce apop-
tosis. Hence, DcR1  or  DcR2  have been postulated to
function as oncogenes because of their postulated anti-
apoptotic effects [111,112]. In cervical carcinoma, a study
has found that all 50 cases analyzed had methylation of
either DcR1 and/or DcR2 [113], suggesting that cervical
cancer cells, by downregulating decoy receptor expres-
sion, obtain a growth advantage.
Table 2: Tumor suppressor genes hypermethylated in invasive cervical cancer
Gene Rate Function Reference
DcR1/DcR2 100% Apoptosis 113
hTERT 57% Apoptosis 122
p73 39% Apoptosis 129
p16 8–42% Cell-cycle 130–136
PTEN 58% WNT-pathway 142
E-cadherin 28–80.5% WNT-pathway 143–145
APC 11–94% WNT-pathway 133,135,136
MGMT 5–81% DNA repair 133,134,136,144
FANCF 30% FA-BRAC pathway 161
BRAC1 6.1% FA-BRAC pathway 133
hMLH1 5% Mismatch repair 134
RASSF1A 0–45% Negative ras-effector 144,172–174
DAPK 45–100% Metastasis/cell death 133,135,136,144
TSLC1 58–65% Tumor suppressor 179,180
FHIT 11–88% DNA repair?/cell death? 133,134,135,136,144
HIC1 18–45% Transcription factor 133,135
RARβ 33–66% Cell differentiation 133,136,200,201
TIMP2/TIMP3 47%/1–10% Tissue inhibitor MTs 144,202,203
Caveolin-1 6% Caveolae membrane 205
ER α 25% Steroid hormone receptor 136Molecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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Telomerase activation is a critical element in cellular
immortalization and cancer. The end of the chromosome,
the telomere, plays a critical role in chromosome structure
and function. A certain length of the telomere is impor-
tant for cell division, and the telomere may serve as a
"mitotic clock" for cell proliferation. Normal human
somatic cells express low or undetectable telomerase
activity, whereas in immortal eukaryotic cells as well as in
cancer cells telomerase activity increase is apparently nec-
essary to ensure proliferation. Telomerase is a ribonucleo-
protein comprising an RNA template, the telomerase-
associated protein, and the catalytic subunit (hTERT)
[114,115]. Telomerase activity has been demonstrated in
various types of gynecologic cancers [116]. Data on hTERT
expression in cervical cancer has revealed that 0–33% of
normal cervices exhibited hTERT  mRNA expression,
whereas 80–100% of cervical cancers showed hTERT
expression [117-120] The fact that the hTERT gene pro-
moter has a CpG island and high overall GC content sug-
gests a possible role for methylation in regulation of
hTERT  gene expression; however, the relationship
between gene promoter and expression is unclear for this
gene. Despite it is expected that hypermethylation
decreases gene expression, a study has found a correlation
between reduced expression and catalytic subunit activity
with demethylation [121]. This may explain what was
found with regard to better prognosis of patients with cer-
vical cancer whose tumors lack hTERT methylation [122].
The p53 pathway responds to stresses that can disrupt the
fidelity of DNA replication and cell division, resulting in
activation of the p53 protein as a transcription factor that
initiates either growth arrest or apoptosis. This apoptosis
pathway is disrupted in the majority of human cancers by
downregulation or loss of p14ARF, upregulation of MDM2,
or mutation of p53 [123,124]. However, this pathway, by
virtue of its multiple positive and negative feedback loops,
can be the target of aberrant methylation in some of their
components.  p73  is a member of the p53  family that
encodes two different proteins expressed under the con-
trol of two independent promoters and that have opposite
activities: the transcriptionally active full-length TAp73
and the NH2-terminally truncated dominant-negative
Np73 [125]. TAp73 has been reported as involved in cellu-
lar response to DNA damage induced by radiation and
chemotherapeutic agents and when it is overexpressed in
cells, it activates transcription of p53-responsive genes
such as p21, Bax, Mdm2, and GADD45 and inhibits cell
growth in a p53-like manner by inducing apoptosis
[126,127]. It has been reported that p73 transcription can
be regulated by the promoter and exon 1, which is rich in
CpG dinucleotides [128], and its transcriptional silencing
through methylation is a common event in some leuke-
mias, lymphomas, and brain tumors, as well as in ovarian
cell lines but not in breast, renal, and colon cancers. A
recent study found that epigenetic modification of p73 via
CpG-island hypermethylation represents a critical alterna-
tive mechanism for inactivation of this gene in cervical
cancer and high incidence of p73  hypermethylation
(38.8%) in cervical cancer but not in controls; in addition,
its methylation was correlated with loss of its p73 expres-
sion. Importantly, radioresistant cancer samples had sig-
nificantly higher methylation rate than radiosensitive
cancer samples, and in vitro demethylation successfully
restored p73 expression in cervical cancer cell lines previ-
ously found to have methylated p73  and lack of p73
mRNA and protein expression [129].
Cell cycle-related genes
It is well-established that cancer cells evolve in part by
overriding normal cell-cycle regulation. Normal cell cycle
progression relies on the cell's ability to translate extracel-
lular signals such as those produced by growth factor
receptor stimulation and extracellular matrices to effi-
ciently replicate DNA and divide. Proper cell- cycle regula-
tion is essential for cells and requires a number of players,
among them cyclin-dependent kinases and their binding
partners along with natural inhibitory molecules such as
p16, Rb, and p15 that play an essential role. Within this
class, the p16 gene has been one of the most studied in
cervical cancer. Aberrant methylation of the p16 gene
occurs early within tumor cell populations in both in situ
and invasive tumors at frequencies that vary from 10 up to
100% [130-136]. As the cell cycle is primarily deregulated
by the HPV, the molecular contribution of p16 inactiva-
tion is unclear; however, the fact that this not only is a very
early event in cervical carcinogenesis but is more fre-
quently methylated in advanced tumors [132] suggests
that its reactivation could have therapeutic value. Despite
the fact that Rb and p15 are known to be inactivated by
methylation in other tumors, no reports exist on cervical
tumors.
WNT pathway
The Wnt signaling pathway, named for its most upstream
ligands, the Wnts, is involved in various differentiation
events during embryonic development and leads to tumor
formation when aberrantly activated. Within this path-
way, there are a number of participating molecules, and
the pathway is regulated by a multiprotein complex con-
sisting of, among others, members of β-catenin, the key
component, adenomatous polyposis coli APC, Axin, and
GSK-3β. [137]. In the absence of Wnt stimulation, β-cat-
enin accumulates in cytosol to then be translocated to
nucleus, leading to transcription of target genes. This
pathway is also involved in calcium-dependent cell adhe-
sion by virtue of the interaction between β-catenin and
cadherin [138]. There are mutations in APC, another key
regulator of the pathway that promotes β-catenin proteol-
ysis and reduces its transcriptional activity. PTEN is a lipidMolecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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and protein phosphatase that is a negative regulator of
phosphatidylinositol 3 (PI-3) kinase-dependent signaling
and influences the WNT pathway by hindering activation
of integrin-linked kinase (ILK), which inhibits GSK-3 β
and thereby causes accumulation of β-catenin [139]. The
WNT signaling pathway is the most frequently altered
pathwayin the majority of cancers; for instance, it has
been demonstrated that nearly all colorectal cancers have
at least one activating mutation in this pathway [140]. As
such, individual components of the pathway can be tar-
geted by epigenetic inactivation. A recent study analyzing
310 colorectal carcinomas for eight members of the sign-
aling cascade, including APC, β-catenin, AXIN2, TCF4,
WISP3, E-cadherin, and PTEN. Hypermethylation on E-
cadherin and APC were found at frequencies between 36
and 42% [141].
Studies on cervical cancer have uncovered that hyper-
methylation of these genes is not uncommon. A study in
62 cases of squamous cell carcinomas showed that while
PTEN mutations were absent, promoter methylation was
found in 58% of cases. Interestingly, patients with persist-
ent disease or patients who died of the disease had a sig-
nificantly higher percentage of PTEN methylation than
those without evidence of recurrence. Multivariate Cox
regression models confirmed PTEN was an important sig-
nificant predictor for both total and disease-free survival
after controlling age, pathologic grade, and clinical stage
[142]. Inactivation of the cadherin-mediated cell adhe-
sion system caused by aberrant methylation is a common
finding in human cancers. Methylation frequency of E-
cadherin in cervical cancer varies from between 28 and
80.5% [143-145] and appears to have prognostic signifi-
cance, cases with no promoter methylation having a better
outcome in univariate and multivariate analyses [146].
Mutations are the main mechanism of inactivation for
APC, particularly for colon and other tumors from the gas-
trointestinal tract. However, APC promoter hypermethyl-
ation occurs in other cancers. Frequencies of methylation
in 208 primary human tumors of multiple origins were as
follows: stomach (13 of 38, 34%); pancreas (6 of 18,
33%); liver (6 of 18, 33%), and esophagus (4 of 27, 15%;
it was less common in tumors of bladder (2 of 19, 10%),
kidney (1 of 12, 8%), or breast (1 of 19, 5%), or was not
observed at all in brain (0 of 10), lung (0 of 17), head and
neck (0 of 10), or ovary (0 of 20) [147]. In endometrial
cancer, hypermethylation occurs at an increased fre-
quency, particularly in MSI+ endometrial tumors [148] as
well as in cervical cancer, with rates varying from 11 to
94% [133,135,136].
DNA repair
Alkyating agents induce O6-alkylguanines that can lead to
mutations and to cell death unless repaired. The major
pathway of repair involves transfer of the alkyl group from
DNA to a cysteine acceptor site in the protein O6-alkyl-
guanine-DNA alkyltransferase. Alkyltransferase brings
about this transfer without The need for cofactors and
DNA is restored completely by the action of a single pro-
tein, but the cysteine acceptor site is not regenerated and
the number of O6-alkylguanines that can be repaired is
equal to the number of active alkyltransferase molecules.
A significant fraction of human tumor cell lines do not
express the alkyltransferase gene; thus, they are much
more sensitive to mutagenesis and killing by alkylating
agents [149]. The MGMT gene product removes muta-
genic and cytotoxic adducts from O(6)-guanine in DNA,
the preferred point of attack of many carcinogens (i.e.,
methylnitrosourea) and alkylating chemotherapeutic
agents (i.e., BCNU, temozolamide, etc.). As a conse-
quence, its lack of expression produces opposite effects for
cancer development and progression: First, tumors
acquire a mutator phenotype characterized by generation
of transition point mutations in key genes such as p53 and
K-ras, but at the same time lack of enzymatic activity
renders tumors more sensitive to the killing effects of
alkylating drugs [150]. While these observations bear clin-
ical and practical implications as predictive or prognostic
markers for response in CNS tumors [151], its silencing by
hypermethylation can be associated with higher stages,
worse survival, or mutations in secondary genes that
adversely affect the prognosis of patients with tumors
such as gastric, colorectal, head, and neck carcinomas,
[152-154] and even in low-grade astrocytomas [155].
There is scarce information concerning the role of MGMT
gene in cervical cancer; a number of studies have analyzed
the frequency of MGMT promoter hypermethylation,
which varies from 5–81% [133,134,136,144]. Interest-
ingly, the five cases with MGMT or BRCA1 methylation
did not respond to chemoradiation [133].
FA-BRCA pathway
Fanconi anemia (FA) is an autosomal recessive chromo-
somal instability syndrome characterized by hypersensi-
tivity to DNA cross-linking agents and predisposition to
cancer, especially leukemia [156]. FA patients are also
prone to various solid malignancies, including squamous
cell carcinoma. FA is a genetically heterogeneous disease
with genes for seven FA complementation (FANC) groups
identified [157]. FANC genes are essential in DNA repair
pathways in normal cellular response to cisplatin and
other DNA cross-linking agents. FANC proteins interact
with BRCA genes in a pathway that involves a number of
other genes [158]. Recently, it has been shown that pro-
moter hypermethylation of FANCF gene disrupts the FA-
BRCA pathway, resulting in cisplatin resistance in ovarian
cancer [159]. FANCF promoter hypermethylation has also
been identified in squamous cell carcinomas of lung and
oral cavity [160]. In cervical cancer, a study has shown
methylation of BRCA1 in 6.1% [133] of invasive tumors,Molecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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whereas FANCF hypermethylation rate was 30% [161].
Interestingly, hypermetylation of these genes was mutu-
ally exlusive in the analyzed cases [161], suggesting the
important role of disruption of this pathway for cancer.
This abnormality seems to be a late event in cervical car-
cinogenesis, as no hypermetylation was observed in any
case of preinvasive disease [161].
Mismatch repair
Cells with dysfunction of mismatch repair genes hMLH1
and hMSH2, as well as hMSH3, hMSH6, and hPMS2,
show mutation rates up to 1,000-fold greater than those
observed in normal cells [162]. The mutator phenotype,
which can be measured by microsatellite instability anal-
ysis, has been detected in tumors of patients with heredi-
tary nonpolyposis colorectal sporadic and other types of
cancers [163]. Mutations and loss of expression due to
gene promoter hypermetylation are the main mecha-
nisms of inactivation of members of this gene family
[164]. Hypermethylation and loss of hMLH1 protein
expression has been associated with chemotherapy resist-
ance in ovarian and other tumors [165]. The relevancy of
this phenomenon has been recently demonstrated by
acquisition of hypermethylation of the gene in relapsed
ovarian cancer after being treated with chemotherapy,
which predicts poor overall survival [166]. Existing data
on cervical cancer with regard to hMHL1 expression status
and methylation is limited. While some studies have
found protein expression loss in invasive lesions [167],
others have found the opposite [168], while presence of
microsatellite instability appears to correlate with a worse
prognosis [169] but not with response to cisplatin in a
neoadjuvant setting [170]. Regarding gene promoter
methylation, its presence is rare in cervical cancers [134].
Miscellaneous
RASSF1A
The Ras Association Domain family 1 (RASSF1A) gene
consists of two main variants (RASSF1A and RASSF1C),
which are transcribed from distinct CpG-island promot-
ers. Aberrant methylation of the RASSF1A promoter
region is one of the most frequent epigenetic inactivation
events detected in human cancer and leads to silencing of
RASSF1A. Hypermethylation of RASSF1A has been
observed in a variety of primary tumors including cervix.
The product of this gene is involved in several important
functions including apoptotic signaling, microtubule sta-
bilization, and mitotic progression and may act as a nega-
tive Ras effector inhibiting cell growth and inducing cell
death. Its loss of expression in several tumor types is
related with worse prognosis [171]. Studies in patients
with cervical cancer have demonstrated its silencing by
methylation in up to 30% of tumors [172-174,144].
DAPK
DAP-kinase (DAPk) is a Ca(2+)/calmodulin (CaM)-regu-
lated Ser/Thr kinase that functions as a positive mediator
of programmed cell death. It associates with actin micro-
filament and has a unique multidomain structure
[175,176]. In cervical cancer, it is methylated in up to
100% of cases [133,135,136,144], which suggests that its
loss of expression is needed for cervical cancer progression
as seen in an experimental model, in which loss of DAP-
Kinase expression aids in metastatic potential of lung can-
cer cells [177].
TSLC1
The recently identified IGSF4/TSLC1 gene codes for an
immunoglobulin Ig-like intercellular adhesion molecule
that mediates calcium-independent homophilic or heter-
ophilic interactions independently of Ca2. This gene was
first identified as a tumor suppressor gene in lung cancer
and silencing can derive from loss of heterozygosity or
promoter hypermethylation [178]. This gene also has
tumor suppressor effects on cervical cancer, as demon-
strated by transfection studies in which IGSF4 cDNA was
introduced into SiHa cells. Transfectants displayed a
marked reduction in anchorage-independent growth and
when injected into nude mice, these were less able to gen-
erate tumors. Progression of the cervical lesion is accom-
panied by loss of expression of IGSF4. In two studies, it
was found that normal epithelium and CIN-1 lesions are
free of methylation at IGSF4, whereas methylation rate in
CIN-III is 35%, which increases to 58 and 65% in invasive
tumors [179,180]. These data demonstrate that IGSF4
may have a role in cervical cancer development.
FHIT
The FHIT gene is a tumor suppressor gene located on
chromosome 3p14.2 and LOH on the short arm of chro-
mosome 3 and has been detected in up to 75% of cervical
carcinomas [181,182]. Many studies have reported altered
FHIT expression in a variety of carcinomas including head
and neck, lung, kidney, gastrointestinal, and breast cancer
and in 68% of cervical carcinoma cell lines [183]. Addi-
tional studies have confirmed that the FHIT gene is abnor-
mally expressed in 30–78% of cervical dysplasia,
carcinoma cell lines, and primary tumors [184-
188,133,134,136,144]. The antitumorigenic mechanism
of FHIT is not yet clear; however, for cervical and lung can-
cer cell lines its reintroduction by use of an adenoviral vec-
tor induces strong suppressive effects and reduces
tumorigenicity due to an apoptotic effect associated with
caspase-8 cleavage and activation of the effector caspase-3
[189]. Hypermethylation of this gene has been associated
with loss of expression and advanced stages of cervical car-
cinoma, suggesting its participation in disease progression
[190].Molecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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HIC1
HIC1 (hypermethylated in cancer) is a tumor suppressor
gene unique in the sense that it has never been found
mutated but is found silenced by hypermethylation. This
gene encodes a zinc-finger transcription factor that
belongs to a group of proteins known as the POZ family.
HIC1 is hypermethylated and transcriptionally silent in
several types of human cancer. Homozygous disruption of
Hic1 impairs development and results in embryonic and
perinatal lethality in mice, while heterozygous mice
develop many different spontaneous malignant tumors
including a predominance of epithelial cancers in males
and lymphomas and sarcomas in females. Complete loss
of Hic1 function in heterozygous mice appears to involve
dense methylation of the remaining wild-type allele pro-
moter [191]. It has recently been shown that its loss of
function accentuates the tumorigenic effect of loss of p53
[192]. It has been found that the HIC1 gene is down reg-
ulated in many cervical cancer cell lines and re-expressed
upon treatment with a demethylating drug [133]. In pri-
mary cervical tumors, its methylation rate varies between
18 and 45% [133,135]. These results support the tumor
suppressor role of HIC1 and its inactivation by promoter
methylation in cervical cancer.
RARβ2
Retinoic acid is essential for regulation of epithelial cell
differentiation. The intracellular effects of RA are medi-
ated by RA-binding nuclear receptors, including RA recep-
tors alpha, beta, and gamma. Ligand-activated receptors
induce transcription of target genes by binding to RA-
responsive elements in promoter regions. One target gene
is the RAR beta gene, which encodes a potential tumor
suppressor. Complete or partial inhibition of gene expres-
sion has been observed in many tumor cell lines and in
primary human tumors [193]. A well-known mechanism
of RAR-β2 inhibition demonstrated in breast and colon
carcinomas is hypermethylation of its promoter [194]. In
cervical cancer, the RARβ2 gene is of particular interest
because retinoic acid inhibits transformation of human
keratinocytes by HPV-16 [196] and leads to regression of
moderate cervical dysplasia [197]. In addition, RA in com-
bination with interferon alfa is a highly effective antitu-
mor therapy for patients with cervical cancer [198].
However, the existence of intrinsic or acquired resistance
to retinoic acid is well-established [199]. Rate of RAR-β2
methylation progressively increases from 11% in low-
grade to 29% in high-grade lesions and from 33–63% in
invasive cancers [133,136,200,201], suggesting that this
abnormality is an early event in multistage cervical car-
cinogenesis.
Tissue inhibitors of metalloproteinases
TIMP-2 and TIMP-3 are endogenous inhibitors of matrix
metalloproteinases that possess growth promoting effect
in cell culture, and anti-tumoral, anti-apoptotic, and anti-
angiogenic effects in animal model systems in vivo. It has
been shown that these endogenous inhibitors are down-
regulated by methylation in cervical carcinomas in a vari-
able proportion of patients [144,202,203] and may
contribute to progression of cervical cancer.
Caveloin
Caveolin-1 is commonly downreglulated in cervical can-
cer cells and its introduction via gene transfer restores
caveolin-1 protein expression and impairs growth in SiHa
cells, which supports its role as a tumor suppressor gene
[204]. Although it is known that HPV-E6 oncoprotein
reduces caveolin expression, in a small percentage of cer-
vical cancer tumors silencing occurs via promoter methyl-
ation [205].
Global hypomethylation
As stated previously, tumor cells may have up to 60% less
global DNA hypomethylation than their normal counter-
parts [77,78] and interestingly, DNA hypomethylation is
progressive from premalignant conditions to fully devel-
oped malignancies [80]. The main mechanisms set for-
ward in attempting to explain cancer causation by
hypomethylation are chromosome instability and reacti-
vation of transposable elements and/or inappropriate
gene activation [81]. Analyses of global DNA methylation
have been performed in samples covering the full spec-
trum of cervical lesions. Kim et al., analyzed 41 samples
from colposcopically identifiable lesions for methylation
by incorporation of [3H]-S-adenosylmethionine. As
expected, the extent of 3H-methyl group incorporation
was increased three- and seven-fold in DNA from cervical
dysplasia and cancer as compared with DNA of normal
cervices and within dysplasias as long as they progress
from normal to low- and high-grade [206]. Subsequently,
this group performed a similar analysis in 83 cases and
obtained essentially the same results with regard to DNA
hypomethylation, highlighting the fact that lower methyl-
ated DNA correlated wtih serum folate levels [207]. Using
a computer-assisted assay based on quantitative analysis
of DNA methylation in individual interphase nuclei by
immunolabelling with anti-5-methylcytosine antibodies,
progressive hypomethylation was observed in dysplastic
and cancer cells as compared to normal controls [208].
These data, along with observations of gene promoter
hypermethylation of a number of genes during pre-inva-
sive to invasive stages of cervical cancer, demonstrate that
both phenomena are coincident during carcinogenesis of
the cervix uteri.
Histone alterations in cervical cancer
At the chromatin level, there are some indications that the
pattern of chromatin distribution in smears may aid in
diagnosis of cervical neoplasia, particularly for glandularMolecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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lesions [209], but the molecular bases for these chromatin
alterations have yet to be determined. Contrariwise, his-
tone changes at a global level in cancer and normal cells
have only recently been studied [210]. A recent report
showed that during the tumorigenic process, cancer cells
had a loss of monoacetylated and trimethylated forms of
histone H4, predominantly at acetylated Lys16 and tri-
methylated Lys20 residues of histone H4, which were
associated with hypomethylation of DNA repetitive
sequences, a hallmark of cancer cells [211]. In this line,
tumor cell acetylation level and methylation of histones
in prostate carcinoma cells identified two disease subtypes
with distinct biological behaviors in patients with pros-
tatic carcinoma [212]. In cervical cancer, it has been
reported that phosphorylated and acetylated forms of his-
tone H3 in cytologic smears shows a marked association
of histone H3 modifications with progression of the dis-
ease from CIN I to CIN II and CIN III [213].
The balance between histone deacetylases and histone
acetyl transferase activities is a major player in regulation
of gene transcription [214]; hence, this balance must be
mantained in normal cells, or otherwise unchecked cell
proliferation and cell death would occur. E6 and E7 onco-
proteins of HPV target numerous cellular proteins to dis-
turb cell growth and proliferation [30] including HDACs
and HATs. The HPV-E7 protein from high-risk types [215]
binds to HDACs, and this interaction occurs through an
intermediary protein called Mi2β, a member of the nucle-
osome remodeling and histone deacetylation (NURD)
complex that possesses the ability to modify chromatin
structure through both deacetylation of histones and ATP-
dependent nucleosome repositioning. Binding of HDACs
to E7 is independent of binding to Rb, and mutations on
E7 abolishes its binding to HDAC1 and results in a loss of
the ability of E7 to efficiently transform rodent fibroblasts
[216]. E6 protein of HPV high-risk types also shares, with
other small DNA tumor viruses, the capacity for targeting
CBP/p300 in an interaction involving the C-terminal zinc
finger of E6 and CBP residues 1808–1826 to downregu-
late p53 transcriptional activity independently of removal
of cellular p53 protein through the proteosome degrada-
tion pathway [217]. As for E7, binding of E6 to the tran-
scriptional co-activator p300/CBP is essential for cell
transformation [218].
Loss of imprinting
Imprinting refers to the condition established during
gametogenesis, dictating that a specific parental allele is or
is not expressed in the offspring. Loss of imprinting is
implicated not only in developmental disorders such as
Prader-Willi syndrome (PWS) and Angelman syndrome
(AS), but also in cancer [219]. In Wilms tumors, loss of
imprinting leads to biallelic expression of IGF2 and recip-
rocal loss of expression of H19, a non-transcribed RNA
with tumor suppressor activities, while IGF2 promotes
tumor formation by inhibiting apoptosis [220,221]. In
cervical cancer, a sole study has found a high frequency of
both loss of heterozygosity and loss of imprinting for H19
and IGF2 genes, suggesting that they participate in the
molecular pathogenesis of cervical cancer [222].
Translational opportunities of epigentic 
alterations in cervical cancer
Identification of numerous epigenetic alterations of cervi-
cal cancer in all stages of the disease process offers new
possibilities of diagnosis and treatment of cervical cancer
(Table 3).
Early detection
Cervical cancer remains a model disease for screening due
to its long natural history and ease of sampling and read-
ing cytologic abnormalities; dramatic reductions in mor-
tality from this neoplasia achieved in countries with well-
organized detection programs validate this fact [223].
Nevertheless, the test as such has low sensitivity, though
high specificity for detecting CIN-3 [224]. More recently,
testing for high-risk types of HPV infection are in use to
aid in the triage of women with atypical squamous cells of
undertermined significance; nonetheless, the large
number of women requiring additional testing and the
inability of cytology or HPV testing to identify women at
higher risk for disease progression impose greater efforts
on health systems. Thus, novel screening alternatives are
needed. The realization that genetic and epigenetic altera-
tions are present at the earliest steps of the malignant pro-
gression of cervix uteri has led to testing the presence of
these abnormalities, such as p16 expression [225,226]. A
large number of studies looking at the methylation status
of tumor suppressor genes have uncovered that some
genes are found hypermethylated in preinvasive lesions,
Table 3: Translational opportunities from epigenetic alterations in cervical cancer
Early detection Identification of a set of hypermethylated genes from cytological smears
Prognostic/predictive Determination of global methylation or histone modifications in tumor or peripheral blood cells Determination of 
hypermethylated gene promoters from serum/plasma DNA
Therapy DNA methylation inhibitors and/or HDACs inhibitors alone or as chemo- or radio-sensitizersMolecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
Page 14 of 24
(page number not for citation purposes)
raising the possibility that testing for methylation of
either of these or a set of these may prove to be a useful
screening tool [133-136]. However, there is limited infor-
mation with respect to the sensitivity and specificity of
methylated genes for identification of women with cervi-
cal dysplasia and cancer as well as comparisons of results
using different sources of samples, either exfoliated cells
or paraffin-embedded fresh biopsy samples. In this
regard, a very comprehensive study investigated the meth-
ylation profile of 20 genes (p16, p15, CCND2, RASSF1,
RARb, TWIST1, SYK, HIC1, VHL, PRDM2, SFN, MLH1,
MGMT, APC, CDH1, and CDH13) in exfoliates and biop-
sies of 319 women that participated in a cytology screen-
ing study. By logistic regression, the authors determined
the best set of candidate genes for employment as a dis-
ease markers. First, they found similar detection rate of
methylation regardless of sample source, and second, they
found that CDH13, DAPK1, RARb, and TWIST1 were the
genes showing statistically signficant increase with lesion
severity, and DAPK1, RARb, and TWIST1, the best panel of
hypermethylated genes. At least one of the three genes was
hypermethylated in 57% of samples with CIN-3/CIS and
in 74% with invasive cancer, but in only 5% of samples
with CIN-1. Estimated specificity of the panel was 95%
with sensitivity of 74% (95% confidence interval [CI 95%
], 73–75%) for invasive carcinoma and 52% (95%,49–
55%) for CIN-3/CIS. These findings provide preliminary
evidence on the potential usefulness of a panel of genes to
be tested for hypermethylation in cytology samples; how-
ever, additional studies are needed before this epigenetic-
based screening test could be adopted [227].
Methylated genes in serum of patients with 
cervical cancer as biomarkers
Circulating nucleic acids represent a biomarker that might
be used in early detection of cancer, in the follow-up of
patients with cancer or as a prognostic factor. Presence of
nucleic acids in plasma or serum of patients with cancer
has been recognized since the 1970s, but it was not until
1989 that the neoplastic characteristics of plasma DNA in
patients with cancer were recognized [228], and this was
followed by detection by PCR-based techniques of specific
gene mutations present in the primary tumor, such as Ras
family members in tumors such as pancreas and myelod-
ysplastic syndromes [229,230]. Within this field of study,
cell-free circulating RNA and nucleosomal DNA have also
been studied in patients with cancer [231,232]. The feasi-
bility of applying a PCR-based technique such as the
Methylaton-Specific PCR (MSP) [233] for amplification
of gene promoters from DNA circulating in serum or
plasma paved the way for the study of epigenetic altera-
tions not only in serum plasma of patients with cancer,
but also in other biologic fluids, such as urine and sputum
[234,235].
The methylation status of several genes present in the
serum or plasma of patients with cervical cancer has been
studied with regard to their prognostic signficance. In a
study analyzing serum samples of 93 patients with the
methyLight technique for gene promoter methylation of
CALCA, hTERT, MYOD1, PR, and TIMP3 genes, methyla-
tion rates were 62, 0, 25, 79, and 4% respectively, and in
all but one case corresponding primary tumors also had
these genes methylated. When authors looked at survival,
methylation of MYOD1  was strongly associated with
shorter, disease-free and overall survival with median sur-
vival of 1.9 and 6.1 years for methylated and unmethyl-
ated cases, respectively [203]. The same group of
researchers reported on the prognostic significance of
CDH1 (E-cadherin) and CDH13 (H-cadherin) using the
same technique and the same number of patients. The
main finding was that aberrant methylation of either
CDH1 or CDH13 was found in 40 (43%) patients, and
median survival for these patients with methylated genes
was 1.2 vs. 4.3 years in CDH1 or CDH13 methylation-free
patients [143]. Data suggesting that methylation of gene
promoters in patients with cervical cancer is a common
phenomenon were reported by another group that ana-
lyzed DAPK, p16, and MGMT genes; these authors also
found a strong correspondence between methylation in
serum and in primary tumors with methylation frequen-
cies in serum of 40, 10, and 7.5% of these genes, respec-
tively [236]. Together, these data encourage further
studies to find a set of methylated genes that would have
prognostic significance but that would also serve as surro-
gate markers of efficacy of epigenetic therapies.
Treatment
Demethylating agents
Reactivation of tumor suppressor genes that have been
silenced by a epigenetic mechanism such as gene pro-
moter methylation is a very attractive molecular target for
cance therapy. Inhibitors of DNA methylation have dem-
onstrated the ability to inhibit hypermethylation, restore
suppressor gene expression, and exert antitumor effects in
in vitro and in vivo laboratory models. There are several
demethylating agents currently being evaluated in preclin-
ical and clinical studies (Table 4). The classical demethyl-
ating agents comprise the analogs of deoxycytidine:5-
azacytidine, 5-aza-2-deoxycytidine, 1-β-D-arabinofuran-
osil-5-azacytosine, and dihydro-5-azacytidine. 5-azacyti-
dine and its analog are the most studied and were
developed over 30 years ago as classical cytotoxic agents,
but were subsequently discovered to be effective DNA
methylation inhibitors [237]; these were tested as such in
several phase II studies against solid tumors demonstrat-
ing very modest activity [238]. To the contrary, their anti-
leukemic activity was very promising and both are being
revived as a consequence of their demonstrated inhibitory
activity upon DNA methylation and gene-reactivatingMolecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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function. Currently, 5-azacytidine is Federal Drug Admin-
istration (FDA)-approved for use against myelodysplastic
syndrome, and the hydrosoluble analog 5-aza-2-deoxycy-
tidine is being tested in a variety of solid tumors as DNA
demethylating agent [239]. Despite the poor activity
against solid tumors of these nucleoside analogs, it is
remarkable that the proof of the concept iwith regard to
the ability of demethylating compounds to demethylate
and reactivate tumor suppresor gene expression has been
demonstrated in solid tumors [136,240]. Whether or not
the reactivating effect can translate into a clinical response
on its own or in combination with classical cytotoxic ther-
apies remains to be demonstrated.
As a second category of demethylating agents, we note the
antisense oligonucleotide MG98 against the 3' untrans-
lated region of DNMT1  mRNA, which codes for the
enzyme DNA methyltransferase 1 that is responsible for
maintenance of DNA methylation [241]. This agent has
shown an ability to inhibit DNMT1 expression without
affecting other DNMTs, and to cause demethylation with
re-expression of p16 in bladder and colon cancer cell lines
as well as to produce tumor growth inhibition in nude
mice bearing human lung and colon xenografts [242].
MG98 has been evaluated in a phase I trial in patients
with advanced or refractory solid tumors and has demos-
trated its tolerability despite the fact that dose-limiting
toxicities of transaminitis, thrombocytopenia, and fatigue
prohibited higher doses. Its molecular efficacy was dem-
onstrated by producing a decrease in DNMT mRNA levels
in six of 10 patients [243].
The fact that deoxycytidine analogs such as current cyto-
toxic agents are not only carcinogenic but also exhibit
neutropenia as their dose-limiting toxicity even when
used at doses required for demethylation [244] has
renewed interest in finding effective and less toxic
demethylating agents. Zebularine is a new oral cytidine
analog originally synthesized as a cytidine deaminase
inhibitor that has been shown to cause demethylation
and reactivation of a silenced and hypermethylated p16
gene in human bladder tumor cells grown in nude mice.
Zebularine was also demonstrated as minimally cytotoxic
in vitro and in vivo and can be given continuously at a
lower dose to maintain demethylation for a prolonged
period, only possible because of its low-toxicity profile; to
date, there are no results of clinical trials with this agent
[245]. Within this class of so-called "non-toxic and orally
administered agents" there is the green tea major polyphe-
nol (-)-epigallocatechin-3-gallate (EGCG), which resulted
as an effective inhibitor of DNMT activity at micromolar
concentrations and that was able to demethylate and reac-
tivate expression of several tumor suppressor genes such
as p16, RAR-β2, and MGMT in cancer cell lines [246].
There is another class of so-called "old drugs" whose
demethylating activity upon gene promoters of tumor
suppressor genes was recently highlighted. Procainamide,
a nonnucleoside inhibitor of DNA methyltransferases
approved for treatment of cardiac arrhythmias, can
demethylate the GSTP1  promoter, a common somatic
genome change in human prostate cancer and reactivates
in vitro and in nude mice the expression of the gene [247].
A related drug, procaine, has also the ability of demethyl-
ating and reactivating tumor suppressor gene expression,
such as the RARβ2 gene in a breast cancer cell line effect
that is accompanied by growth-inhibitory actions [248].
Our group has recently shown in vitro and in vivo pro-
moter demethylation and tumor suppressor gene tran-
scriptional reactivation mediated by the antihypertensive
compound hydralazine, a well-tolerated drug devoid of
the common side effects of cytotoxic chemotherapy
agents [249]. Its DNA demethylating activity can be
explained by the interaction between its nitrogen atoms
with residues Lys162 and Arg240 of the DNA methyl-
transferase active site, as shown in a silico modeling [250].
Histone deacetylase inhibitors
HDACs are seen as a potential target for cancer treatment.
HDAC inhibition has been reported to induce tumor cell
differentiation, apoptosis, or growth arrest, depending on
the experimental system [251,252], and to sensitizer cells
to chemotherapy [253] or radiation therapy [254] How-
ever, the HDAC-dependent mechanisms accounting for
the observed and rather selective modulation of gene
Table 4: Epigenetic therapy agents
DNA methylation inhibitors
deoxycytidine analogs:
5-azacytidine, 5-aza-2-deoxycytidine, 1-β-D-arabinofuranosil 5-
azacytosine, dihydro- 5-azacytidine
nucleic acid-based:
MG98 antisense oligonucleotide
cytidine deaminase analogs:
zebularine
non-nucleoside analogs:
(-)-epigallocatechin-3-gallate, procaine, procainamide, hydralazine
Histone deacetylase inhibitors
Small molecular weight carboxilates:
sodium butyrate, valproic acid, sodium phenylbutyrate and 
pivaloyloxymethyl butyrate
Hydroxamic acids:
SAHA, trichostatin A, SBHA
Benzamides:
CI-994, MS-275
Epoxyketones:
trapoxin B, 2-amino-8-oxo-9,10-epoxydecanoic acid
Cyclic peptides:
apicidin, depsipeptide
Hybrid molecules:
CHAP 31, CHAP50Molecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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expression, as well as specific patterns of antitumor activ-
ity, remain poorly understood.
Currently, there are six structurally distinct classes of
HDAC inhibitors at diverse stages of preclinical and clini-
cal development (Table 4); these act by binding to various
portions of catalytic domains within class I and II HDACs:
1) Small molecular weight carboxilates (sodium butyrate,
valproic acid, sodium phenylbutyrate and pivaloyloxyme-
thyl butyrate); 2) hydroxamic acids (suberoylanilide
hydroxamic acid -SAHA-, trichostatin A, suberic bishy-
droxamic acid -SBHA-, and others); 3) benzamides (CI-994
and MS-275); 4) epoxyketones (trapoxin B, HC-toxin, or 2-
amino-8-oxo-9,10-epoxydecanoic acid); 5) cyclic peptides
(apicidin, depsipeptide), and 6) hybrid molecules CHAP 31
and CHAP50) [255].
In general, HDAC inhibitors are at most at the early stages
of clinical development. Among them, SAHA has shown
in a recently reported phase I study of 73 patients with
advanced cancer a complete response in a patient with
transformed diffuse large B-cell lymphoma for 17
months, three partial responses in B-cell lymphoma,
laryngeal cancer, and papillary thyroid cancer, and pro-
longed stabilization in patients with renal carcinoma
[256]. In another study of MS-275 in 31 heavily pre-
treated patients despite the fact that no objective
responses were observed, 15 cases achieved disease stabi-
lization for 62–309 days [257]. In another phase I study
with CI-994, one of 42 patients with a pre-treated lung
adenocarcinoma showed a partial response over 2 years,
whereas three additional patients with small-cell lung
cancer, colorectal, and renal carcinoma had stable disease
[258]. In a phase II study of pivaloyloxymethyl butyrate in
pre-treated non small-cell lung cancer, three (6.4%) of 47
patients achieved partial responses and 14 (30%) patients
achieved stable disease [259].
The strong interplay between DNA hypermethylation and
histone deacetylation for silencing and modulating the
expression of a number of cancer-related genes predicts
not only a synergy in gene expression at global [260] and
individual gene levels [261] but also in antitumor activity.
For instance, combinations of decitabine with trichostatin
A or depsipeptide synergistically reactivate silenced tumor
suppressor genes including MLH1,  TIMP3,  CDKN2B,
CDKN2A,  ARHI,  gelsolin, and maspin  [262-264] and
increase the level of tumor cell apoptosis [265]. Thus, a
logical step forward is to combine a demethylating with a
histone deacetylase inhibitor for cancer treatment.
Epigenetic therapy in cervical cancer
Despite ample experimental evidence supporting the
development of drugs that target the epigenoma via inhi-
bition of DNA methylation or histone modification as
cancer therapy, clinical results are pending to date. At
present, the majority of the information has been gener-
ated in hematologic neoplasms and advanced or refrac-
tory solid tumors. The main findings of this form of
therapy in cervical cancer are depicted in Table 5.
Decitabine was used against advanced or recurrent cervi-
cal carcinoma in a small phase II study at a time when it
was already known that this drug was a demethylating
agent. The schedule used was 75 mg/m2 per hour 3 times
on day 1 at 7-hours intervals and repeated every 5 weeks.
None of the 14 patients evaluated for response responded
or even had disease stabilization, and one patient died
from neutropenic sepsis [266]. Aparicio et al. reported a
phase I study using 5-aza-2'-deoxycytidine in patients
with advanced solid tumors using escalating doses of 20,
30, and 40 mg/m2 employing a 72-hour continuous infu-
sion every 28 days. Quantitative Methyl-Light reaction
was used to evaluate changes in promoter methylation in
19 genes, but no consistent evidence of gene demethyla-
tion was documented despite the fact that grade 4 neutro-
penia was found in nearly one third of the patients. This
latter finding argues against its use as a DNA demethylat-
ing agent in solid tumors because despite such toxicity,
steady-state levels reached during the study (0.1–0.2 µM)
are below levels needed in vitro to demethylate gene pro-
moters [244]. On the other hand, a number of genes
showed increased methylation, which could be derived
from the cytotoxicity of this nucleoside analog. It is well-
known that the majority of cytotoxic agents lead to
increase in DNA methylation in vitro and in cancer
Table 5: Main findings of epigenetic therapy in cervical cancer
Lack of response to DNA methylation inhibitor 5-aza-2-deoxycytidine 
as a single agent in advanced or recurrent cervical cancer*
Response rate of 38.1% with the DNA methylation inhibitor 5-aza-2-
deoxycytidine plus cisplatin in advanced or recurrent cervical cancer*
Demethylation and reactivation of the expression of several tumor 
suppressor genes in the tumors of cervical cancer patients in a phase I 
trial of the DNA methylation inhibitor hydralazine
Sustained stabilization of disease in a patient with cervical cancer 
treated within a phase I trial of the HDAC inhibitor MS-275
Major response in a patient with cervical cancer being treated with 
the HDAC inhibitor valproic acid followed by a single dose of 
epirubicin within a phase I trial
H3 and H4 hyperacetylation as well as inhibition of deacetylase 
activity in the tumors of cervical cancer patients with cervical cancer 
in a phase I trial of the HDAC inhibitor magnesium valproate
Ongoing phase II trial of the combination of hydralazine and 
magnesium valproate added to cisplatin chemoradiation in FIGO stage 
IIIB patients
*DNA methylation was not analyzed in these trials.Molecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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patients [267]. In an attempt to exploit the synergism
observed between decitabine and cisplatin, a phase II
study with this combination was performed in advanced
or recurrent cervical cancer. Initial dose of cisplatin was 40
mg/m2, whereas decitabine dosage was 50 mg/m2 for 3
consecutive days every 21 days. Due to toxicity, the cispl-
atin dose was reduced to 30 mg/m2. Twenty five patients
were included in the study; 24 were eligible for evaluation
of toxicity, whereas 21 were eligible for evaluation of
tumor responses. A total of 75 cycles of chemotherapy
were administered to patients, with a median of three
cycles (range: 1–8 cycles per patient). The most frequently
observed side effect was grade III and IV neutropenia in
68.0% of cases; one patient died of complications caused
by drug-related neutropenic sepsis. Of a total of 21
patients evaluable for tumor response, eight (38.1%)
achieved a partial response, whereas stable disease was
documented in five cases (23.8%); median survival was 5
months [268]. DNA methylation at global or individual
gene was not evaluated; thus, the merit of this combina-
tion as DNA methylation-targeted therapy remains to be
established. Among other DNA demethylating agents, in
a phase I study hydralazine was administered to cohorts
of four patients at the following dose levels: 1) 50 mg/day;
11) 75 mg/day; III) 100 mg/day, and IV), 150 mg/day.
Tumor biopsies and peripheral blood samples were taken
the day before and after treatment to analyze by MSP and
RT-PCR the genes APC, MGMT; ER, GSTP1, DAPK, RARβ,
FHIT, and p16 pre- and post-treatment for DNA promoter
methylation and gene expression. The drug was well-tol-
erated and rates of demethylation at the different dose lev-
els were as follows: 50 mg/day, 40%; 75 mg/day, 52%;
100 mg/day, 43%, and 150 mg/day, 32%; nine of 12
informative cases (75%) re-expressed the gene. Interest-
ingly, there was neither change in methylation status of
H19 and clone 1.2 nor changes in global DNA methyla-
tion in peripheral blood mononuclear cells [136].
With regard to histone deacetylase inhibitors for cervical
cancer, limited clinical information obtains from a phase
I study of MS-275; a patient with cervical cancer had a sus-
tained period of 10 months of stable disease [257], sup-
porting the potential activity of this class of drugs for this
tumor type. Also encouraging are recent data from a phase
I study for metastatic solid tumors in which valproic acid
was administered as an IV loading dose followed by five
oral doses were administered every 12 hours followed by
a dose of epirubicin at day 3. At the time of reporting, 16
patients have been treated at four dose levels: VPA 15, 30,
45, and 60 mg/kg, with epirubicin at 75 mg/m2. The max-
imum tolerated dose has not been reached and dose esca-
lation is continuing. Major responses were observed in all
tumor types including in anthracycline failures and in
anthracycline-resistant cancers such as melanoma and cer-
vical carcinoma, suggesting that inhibition of HDAC
activity may chemosensitize tumor cells [269]. Use of val-
proic acid in the form of magnesium valproate was
recently reported in a phase I study where 12 newly diag-
nosed patients with cervical cancer were treated after a
baseline tumor biopsy and blood sampling at the follow-
ing dose levels (four patients each): 20 mg/kg; 30 mg/kg,
or 40 mg/kg for 5 days via oral route; at day 6, when
steady state of valproic acid was achieved, tumor and
blood sampling were repeated. All patients completed the
study medication and mean daily dose for all patients was
1,890 mg with depressed level of consciousness grade 2 as
most frequent toxicity. After treatment, there was hyper-
acetylation of H3 and H4 in tumors of nine and seven
patients, respectively, whereas six patients demonstrated
hyperacetylation of both histones, and tumor deacetylase
activity decreased in eight patients (80%). These data
demonstrate for the first time that magnesium valproate
at a dose between 20 and 40 mg/kg inhibits deacetylase
activity and hyperacetylates histones in malignant solid
tumors [270]
It is remarkable that DNA methylation inhibitors such as
decitabine [271] and zebularine [272] as well as HDAC
inhibitors including SAHA, M344, depsipeptide [273],
and valproic acid [274] are radiosensitizers. In addition, it
is very noteworthy that HDAC inhibitors such as phenyl-
butyrate, trichostatin A, and valproic acid are able to
reduce cutaneous radiation toxicity following radiother-
apy [275]. Therefore, radiation or chemoradiation in
combination with DNA demethylating agents and/or
HDAC inhibitors is a research avenue to be explored.
Based on these data, a phase II study of transcriptional
therapy with the demethylating hydralazine plus the his-
tone deacetylase inhibitor magnesium valproate added to
chemoradiation with cisplatin is ongoing in FIGO stage
IIIB cervical carcinoma.
Conclusion
Epigenetic alterations are at least if not more important
than genetic defects for the development and progression
of malignant diseases. In cervical cancer, a number of epi-
genetic alterations occurring during all stages of cervical
carcinogenesis in both human papillomavirus and host
cellular genomes have been identified. These include glo-
bal DNA hypomethylation, hypermetylation of key tumor
suppressor genes, and histone modifications. From the
diagnostic point of view, because epigenetic abnormali-
ties occur very early in the carcinogenic process they can
potentially be exploited as molecular markers for early
detection. In this sense, identification of a set of genes
hypermetylated in cytologic smears could offer novel
means for screenning. Assessment of hypermethylated
genes in primary tumor or in serum DNA may serve as a
prognostic factor or as a means of predicting response to
radiation, chemotherapy, and transcriptional agents.Molecular Cancer 2005, 4:38 http://www.molecular-cancer.com/content/4/1/38
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In the therapeutic field, transcriptional therapy is a very
promising form of cancer treatment that is being exten-
sively evaluated. It is too early to evaluate usefulness.
However, it has now been demonstrated that inhibitors of
DNA methylation and histone deacetylases can reactivate
expression of tumor suppressor genes and induce hystone
hyperacetylation in the tumors of patients with cervical
cancer after treatment with these agents.
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